BNP Paribas Increases Stock Position in Zoetis Inc. $ZTS

BNP Paribas boosted its position in Zoetis Inc. (NYSE:ZTS) by 10.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 169,600 shares of the company’s stock after acquiring an additional 16,150 shares during the period. BNP Paribas’ holdings in Zoetis were worth $24,485,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of ZTS. Halbert Hargrove Global Advisors LLC increased its holdings in Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares during the period. Financial Consulate Inc. bought a new position in Zoetis during the 3rd quarter valued at approximately $39,000. SJS Investment Consulting Inc. lifted its holdings in Zoetis by 1,606.3% in the 3rd quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock worth $40,000 after buying an additional 257 shares during the period. TruNorth Capital Management LLC bought a new stake in shares of Zoetis in the 3rd quarter worth approximately $42,000. Finally, Financial Gravity Companies Inc. bought a new stake in shares of Zoetis in the 2nd quarter worth approximately $47,000. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Up 0.1%

Shares of NYSE:ZTS opened at $115.62 on Friday. Zoetis Inc. has a 52-week low of $114.47 and a 52-week high of $172.23. The firm has a market capitalization of $48.81 billion, a P/E ratio of 19.21, a P/E/G ratio of 1.76 and a beta of 0.95. The stock has a 50 day moving average price of $125.34 and a 200-day moving average price of $131.75. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm’s revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s payout ratio is 35.22%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ZTS shares. Bank of America upped their target price on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Friday, February 13th. William Blair reiterated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Stifel Nicolaus reduced their price objective on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research report on Tuesday, November 18th. UBS Group set a $136.00 price objective on shares of Zoetis in a report on Thursday, January 29th. Finally, Morgan Stanley set a $160.00 target price on shares of Zoetis in a research report on Thursday, December 18th. Six analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.